1,211 results on '"Nakamura, Toshitaka"'
Search Results
2. Correction: Risk factors for incident vertebral fractures in osteoporosis pharmacotherapy: a 2-year, prospective, observational study
3. PRDX6 dictates ferroptosis sensitivity by directing cellular selenium utilization
4. Integrated chemical and genetic screens unveil FSP1 mechanisms of ferroptosis regulation
5. Reliability of early stage symptoms/clinical findings of osteonecrosis of the jaw: Japanese Osteoporosis Intervention Trial-05 (JOINT-05)
6. Optimal Catheter Selection for Patients with Acute Stroke with Type III Aortic Arch Based on Magnetic Resonance Angiography Road Mapping of the Para-Aortic Transfemoral Access Route Before Mechanical Thrombectomy
7. A tangible method to assess native ferroptosis suppressor activity
8. Phase separation of FSP1 promotes ferroptosis
9. DHODH inhibitors sensitize to ferroptosis by FSP1 inhibition
10. Effect of Bone Resorption Inhibitors on Serum Cholesterol Level and Fracture Risk in Osteoporosis: Randomized Comparative Study Between Minodronic Acid and Raloxifene
11. The Interaction of Acute‐Phase Reaction and Efficacy for Osteoporosis After Zoledronic Acid: HORIZON Pivotal Fracture Trial
12. Sequential therapy with once-weekly teriparatide injection followed by alendronate versus monotherapy with alendronate alone in patients at high risk of osteoporotic fracture: final results of the Japanese Osteoporosis Intervention Trial-05
13. A non-canonical vitamin K cycle is a potent ferroptosis suppressor
14. Influence of symptomatic periodontal disease on changes in skeletal bone density during medication therapy for osteoporosis in postmenopausal women: the Japanese Osteoporosis Intervention Trial (JOINT)-04 and JOINT-05
15. Exploiting ferroptosis vulnerabilities in cancer
16. PRDX6 dictates ferroptosis sensitivity by directing cellular selenium mobilization
17. Relationship Between Changes in Serum Levels of Intact Parathyroid Hormone and Sclerostin After a Single Dose of Zoledronic Acid: Results of a Phase 1 Pharmacokinetic Study
18. Impact of bone mineral density in reducing fracture risk in patients receiving alendronate plus alfacalcidol therapy
19. Acute Phase Reactions After Intravenous Infusion of Zoledronic Acid in Japanese Patients with Osteoporosis: Sub-analyses of the Phase III ZONE Study
20. Risk factors for incident vertebral fractures in osteoporosis pharmacotherapy: a 2-year, prospective, observational study
21. Assessing the activity of benzodioxol, phenol and aniline derivatives as radical trapping antioxidants that inhibit ferroptosis
22. Complication rate, cure rate, and long-term outcomes of microsurgery for intracranial dural arteriovenous fistulae: a multicenter series and systematic review
23. Functional analysis of FSP1 and its novel inhibitors
24. Relationship Between Bone Mineral Density and Risk of Vertebral Fractures with Denosumab Treatment in Japanese Postmenopausal Women and Men with Osteoporosis
25. Efficacy of denosumab co-administered with vitamin D and Ca by baseline vitamin D status
26. Odanacatib for the treatment of postmenopausal osteoporosis: results of the LOFT multicentre, randomised, double-blind, placebo-controlled trial and LOFT Extension study
27. Iron homeostasis and iron-regulated ROS in cell death, senescence and human diseases
28. The mitochondrial Ca2+ uptake regulator, MICU1, is involved in cold stress-induced ferroptosis
29. A Pilot Study on Measuring Tissue Motion During Carotid Surgery Using Video-Based Analyses for the Objective Assessment of Surgical Performance
30. Study design of multi-center, open-label randomized controlled, head-to-head trial comparing minodronic acid and raloxifene: Japanese Osteoporosis Intervention Trial (JOINT)-04
31. Changes in quality of life in patients with postmenopausal osteoporosis receiving weekly bisphosphonate treatment: a 2-year multicenter study in Japan
32. Effects of 3-year denosumab treatment on hip structure in Japanese postmenopausal women and men with osteoporosis
33. Improved periodontal disease and prevention of tooth loss in osteoporosis patients receiving once-yearly zoledronic acid: a randomized clinical trial
34. Monthly oral ibandronate 100 mg is as effective as monthly intravenous ibandronate 1 mg in patients with various pathologies in the MOVEST study
35. Tissue Acceleration as a Novel Metric for Surgical Performance During Carotid Endarterectomy
36. Do Children Motivate Their Parents to Play Digital Games?: Child-Rearing vs. Intrafamilial Externality.
37. Postoperative Adjuvant Anastrozole for 10 or 5 Years in Patients With Hormone Receptor–Positive Breast Cancer: AERAS, a Randomized Multicenter Open-Label Phase III Trial
38. Surgical Outcomes for Cervical Carotid Artery Stenosis: Treatment Strategy for Bilateral Cervical Carotid Artery Stenosis
39. Efficacy on the risk of vertebral fracture with administration of once-weekly 17.5 mg risedronate in Japanese patients of established osteoporosis with prevalent vertebral fractures: a 156-week longitudinal observational study in daily practice
40. Comparison of concurrent treatment with vitamin K2 and risedronate compared with treatment with risedronate alone in patients with osteoporosis: Japanese Osteoporosis Intervention Trial-03
41. 24-Month Open-Label Teriparatide Once-Weekly Efficacy Research Trial Examining Bone Mineral Density in Subjects with Primary Osteoporosis and High Fracture Risk
42. Osteoblast Development in Bone Loss Due to Skeletal Unloading
43. Comparison of Access Route for Endovascular Treatment by Time-Spatial Labeling Inversion Pulse (Time-SLIP) MRA and Contrast-Enhanced MRA
44. Insulinogenic sucrose + amino acid mixture ingestion immediately after resistance exercise has an anabolic effect on bone compared with non-insulinogenic fructose + amino acid mixture in growing rats
45. The effects of once-weekly teriparatide on hip geometry assessed by hip structural analysis in postmenopausal osteoporotic women with high fracture risk
46. Efficacy, tolerability and safety of once-monthly administration of 75 mg risedronate in Japanese patients with involutional osteoporosis: A comparison with a 2.5 mg once-daily dosage regimen
47. Serum 25-Hydroxyvitamin D Level as an Independent Determinant of Quality of Life in Osteoporosis With a High Risk for Fracture
48. Effect of monthly intravenous ibandronate injections on vertebral or non-vertebral fracture risk in Japanese patients with high-risk osteoporosis in the MOVER study
49. Decreased rate of hip fracture and consequent reduction in estimated medical costs in Japan
50. Safety, pharmacokinetics, and changes in bone metabolism associated with zoledronic acid treatment in Japanese patients with primary osteoporosis
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.